Epigenomics AG Reports Positive Results in Clinical Study for Epi ProColon 2.0.
9/19/2011 8:09:57 AM
(RTTNews) - Epigenomics AG (ECX.DE,EPGNF.PK: News ) Monday reported positive results in a clinical study for the company's second generation blood-based test for the early detection of colorectal cancer, Epi proColon 2.0. In the study, 98 patients with colorectal cancer and 149 patients with no evidence of disease as verified by colonoscopy were tested with the Epi proColon 2.0 test. The test identified 95% of the cancer cases at a specificity of 85%. The new study provides the clinical evidence required for CE-marking of Epi proColon 2.0 for launch in the European market later this year. The study is expected to be initiated and completed in time for a submission to FDA before year-end 2011.
comments powered by